WebDoctor Encyclopedia

Gastrointestinal Genitourinary Soft-tissue sarcomas Uterine

PEComa (perivascular epithelioid cell tumour)

PEComa is a rare tumour made of perivascular epithelioid cells, which show both pigment-cell and smooth-muscle features. It mostly affects adult women, often in the uterus or gut, ranges from benign to malignant, and advanced disease can respond to mTOR inhibitors.

Medically reviewed Last reviewed October 19, 2026

What is PEComa?

PEComa stands for perivascular epithelioid cell tumour. It is a rare tumour of soft tissue and internal organs built from an unusual cell type, the perivascular epithelioid cell (PEC), which tends to gather around the walls of small blood vessels.

PEC cells are puzzling because they carry features of two different cell families at once: they make proteins normally found in pigment cells (melanocytes) and proteins normally found in smooth muscle. No normal counterpart of this cell has ever been clearly identified in healthy tissue.

The name PEComa is used in two ways. In a broad sense it covers a family of related tumours, including angiomyolipoma of the kidney, lymphangioleiomyomatosis (LAM) of the lung and the clear cell “sugar” tumour of the lung. In a narrow sense, and in this article, it refers to PEComa not otherwise specified (NOS), the member of the family that can arise almost anywhere in the body.

Most PEComas are found in adult women, and the uterus and gut are among the commonest sites. Many behave in a benign way, but a proportion are malignant and can spread to the lungs, liver or bones (Izubuchi and Tanaka, 2025).

Some PEComas are linked to tuberous sclerosis complex (TSC), an inherited condition. This link explains why medicines that block the mTOR pathway can shrink advanced tumours.

1. Key facts at a glance

Feature Details
Type of tumour Mesenchymal (connective tissue) tumour made of perivascular epithelioid cells
How common Very rare; probably fewer than 1 new case per million people each year for PEComa NOS
Typical age Adults, most often 30-60 years; children occasionally
Sex Clearly more common in women
Common sites Uterus, stomach and bowel, retroperitoneum, abdominal wall and pelvis, kidney, liver, bladder, skin
Behaviour From benign to malignant; judged by size and microscopic features
Main treatment Complete surgical removal
Advanced disease mTOR inhibitors such as nab-sirolimus, sirolimus or everolimus
Outlook Excellent for benign-type tumours; serious when malignant and spread

2. The PEComa family

Family member Usual site Notes
Angiomyolipoma Kidney, sometimes liver Contains fat, muscle-like cells and thick vessels; usually benign; common in TSC
Epithelioid angiomyolipoma Kidney A variant with more potential to behave aggressively
Lymphangioleiomyomatosis (LAM) Lungs, lymph nodes Causes cysts in the lungs, almost always in women
Clear cell “sugar” tumour Lung Small benign nodule, usually found by chance
PEComa NOS Uterus, gut, soft tissue and many organs The focus of this article

3. Causes and risk factors

In most people the cause of PEComa is not known. There is no known link with diet, lifestyle, injury or infection.

Gene changes

Researchers have found two main groups of gene changes in PEComa:

Group Gene change What it does Notes
TSC-related Loss of TSC2 or, less often, TSC1 Switches on the mTOR growth pathway The commonest group; explains response to mTOR inhibitors
TFE3-rearranged TFE3 gene fusion Overactivates a gene that controls cell metabolism Often younger patients; nested clear cells; may respond less well to mTOR drugs

These gene changes are usually found only in the tumour cells. They are not passed on to children (Izubuchi and Tanaka, 2025).

Tuberous sclerosis complex

A minority of people with PEComa NOS have tuberous sclerosis complex, an inherited condition caused by a faulty TSC1 or TSC2 gene. TSC also causes skin patches, seizures, kidney angiomyolipomas and LAM. Doctors may suggest genetic assessment if there are other signs of TSC or more than one tumour.

Risk factor Notes
Female sex Women are affected several times more often than men
Tuberous sclerosis complex Raises the risk of several PEComa family tumours
Age Mostly working-age adults

4. How does it look

To the patient

Many PEComas are deep inside the body and cannot be seen or felt. When they are near the surface, for example in the abdominal wall or limbs, they may feel like a firm, painless lump. Skin PEComas look like a small pink or skin-coloured bump.

During surgery

Feature Description
Shape A rounded or lobulated mass, sometimes with a thin capsule
Size From under 2 cm to over 20 cm; malignant tumours are often larger
Cut surface Grey-tan, pale yellow or reddish
Bleeding and dead tissue Common in larger, more aggressive tumours
Edges Pushing in benign tumours; infiltrating nearby tissue in malignant ones

On scans

On CT and MRI, PEComa usually appears as a well-defined mass with a rich blood supply that lights up strongly after contrast. Bleeding, dead areas and, in angiomyolipoma, fat may also be seen. These findings are suggestive but not specific, so a biopsy or removal is needed for diagnosis.

Under the microscope

Feature Description
Cells Epithelioid (rounded) or spindle-shaped cells with clear to pink, grainy cytoplasm
Arrangement Nests and sheets around thin blood vessels
Melanocytic markers HMB-45 and Melan-A positive
Muscle markers Smooth muscle actin and desmin often positive
Other stains Cathepsin K positive; TFE3 strongly positive in TFE3-rearranged tumours
Not seen S100 and SOX10 are usually negative, which helps separate PEComa from melanoma

5. Symptoms

Symptoms depend mainly on where the tumour grows and how big it is. Small tumours often cause no symptoms and are found by chance on a scan done for another reason.

Common symptoms by site

Site Possible symptoms
Uterus Heavy, irregular or post-menopausal bleeding; pelvic pain or pressure
Stomach or bowel Tummy pain, bleeding, anaemia, a change in bowel habit, blockage
Retroperitoneum and abdomen Swelling, fullness, back or tummy pain
Kidney Blood in the urine, flank pain
Liver Discomfort under the right ribs; often no symptoms
Bladder Blood in the urine, needing to pass urine often
Skin or soft tissue A slowly growing lump

General symptoms

  • Tiredness, often from anaemia caused by bleeding
  • Weight loss in advanced disease
  • Sudden pain if a tumour bleeds internally

Symptoms of spread

Site of spread Possible symptoms
Lungs Cough, breathlessness
Liver Tummy pain, jaundice
Bone Bone pain, fracture
Peritoneum Abdominal swelling, fluid in the abdomen

When to seek medical advice

See a doctor about unusual vaginal bleeding, blood in the urine or stool, a lump that is growing, or tummy pain or swelling that does not settle. These symptoms have many common causes, but they should always be checked.

6. Diagnosis

Test Purpose
Clinical examination Checks for a lump and signs of tuberous sclerosis
Ultrasound, CT or MRI Shows the size and position of the tumour and any spread
PET-CT Sometimes used to look for spread
Biopsy or surgical removal Provides tissue for diagnosis
Immunohistochemistry Shows the typical mix of melanocytic and muscle proteins
Molecular testing Looks for TFE3 fusions or TSC1 or TSC2 changes
Endoscopy, cystoscopy or hysteroscopy Examines the gut, bladder or womb lining when those organs are involved

Is it benign or malignant?

Pathologists use the Folpe criteria to estimate the risk of spread (Folpe et al., 2005). The main warning features are:

Warning feature Notes
Size over 5 cm Larger tumours behave worse
Infiltrative growth Tumour cells invade nearby tissue
High nuclear grade and cellularity Very abnormal, crowded cells
Mitoses more than 1 per 50 high-power fields A sign of fast cell division
Necrosis Areas of dead tumour
Vascular invasion Tumour cells inside blood vessels
Category Definition Usual behaviour
Benign No warning features Very unlikely to come back or spread
Uncertain malignant potential Only large size, or only nuclear atypia with multinucleated giant cells Low risk, but follow-up advised
Malignant Two or more warning features Risk of recurrence and spread

Uterine PEComas are assessed with a modified set of criteria designed for the womb, but the principle is the same.

Conditions that can look similar

PEComa can be mistaken for melanoma, gastrointestinal stromal tumour (GIST), leiomyosarcoma, clear cell sarcoma and renal cell carcinoma. A specialist sarcoma pathologist should review the diagnosis.

7. Treatment

Treatment is planned by a sarcoma multidisciplinary team, including surgeons, oncologists, radiologists and pathologists.

Surgery

Complete removal with clear margins is the main treatment for PEComa that has not spread. The type of operation depends on the site:

Site Typical operation
Uterus Hysterectomy, or removal of the tumour alone in selected cases
Stomach or bowel Removal of the affected segment
Kidney Partial or complete nephrectomy
Liver Liver resection
Soft tissue Wide excision

Treatment for advanced or spread disease

Option Notes
nab-sirolimus An albumin-bound form of sirolimus approved in the USA for advanced malignant PEComa; in the AMPECT trial about 4 in 10 people had tumour shrinkage, often lasting years (Wagner et al., 2021; Wagner et al., 2024)
Sirolimus, everolimus or temsirolimus Tablet or infusion mTOR inhibitors used in many countries; responses reported in many small series
Chemotherapy Doxorubicin, gemcitabine or other sarcoma drugs; limited benefit
VEGF-targeted drugs Such as pazopanib, in selected cases
Radiotherapy To control pain or local disease
Clinical trials Recommended where available

Tumours with TSC2 changes seem more likely to respond to mTOR inhibitors than TFE3-rearranged tumours (Wagner et al., 2021).

Side effects of treatment

Treatment Possible side effects
Surgery Pain, infection, bleeding, loss of function of the affected organ
mTOR inhibitors Mouth ulcers, tiredness, rash, raised blood sugar and cholesterol, low blood counts, lung inflammation (pneumonitis), more infections
Chemotherapy Nausea, hair loss, low blood counts, tiredness
Radiotherapy Skin soreness, tiredness, effects on nearby organs

8. Outlook (prognosis)

The outlook for PEComa varies widely and depends mostly on whether the tumour is benign or malignant.

Situation Usual outlook
Benign-type tumour, completely removed Excellent; most people are cured
Uncertain malignant potential Generally good, but long-term follow-up is needed
Malignant, localised and removed Recurrence or spread in a substantial proportion
Metastatic disease Serious, but mTOR inhibitors can control the disease for long periods in some people

Spread most often affects the lungs, liver, bones and peritoneum, and can appear years after surgery (Folpe et al., 2005).

9. Follow-up

Follow-up Purpose
Clinic review Check for symptoms and examine the area
CT or MRI scans Every 3-6 months at first for malignant tumours, then less often
Chest imaging To detect lung spread early
Long-term review Advised for many years, as late relapse can occur
Blood tests during mTOR treatment Blood counts, sugar, cholesterol and kidney function

10. Living with PEComa

  • Keep all follow-up appointments, even if you feel well
  • Report new symptoms such as bleeding, pain, cough or weight loss
  • Use a soft toothbrush and mouthwash if you take an mTOR inhibitor, to reduce mouth ulcers
  • Tell all your doctors about mTOR medicines, which can interact with other drugs and vaccines
  • Ask about genetic assessment if you or relatives have signs of tuberous sclerosis
  • Seek support from sarcoma charities and rare cancer groups

11. Frequently asked questions

Question Answer
Is PEComa cancer? Some PEComas are benign and some are malignant (a type of sarcoma)
Is PEComa inherited? Usually not, but some people have tuberous sclerosis, which is inherited
Is it the same as angiomyolipoma? They are related members of the same family but are classed separately
Why is it treated with sirolimus? Many PEComas have overactive mTOR signalling, which sirolimus blocks
Can PEComa come back after surgery? Benign tumours rarely do; malignant ones can, sometimes years later
Can I still have children? This depends on the site and surgery; ask about fertility options before uterine surgery

12. Questions to ask your care team

  • Is my tumour benign, uncertain or malignant, and why?
  • Was it completely removed?
  • Has it been tested for TFE3 or TSC2 changes?
  • Should I be checked for tuberous sclerosis?
  • Would an mTOR inhibitor or a clinical trial suit me?
  • How often will I need scans, and for how long?

Resources

  1. Folpe, A.L. et al. (2005) ‘Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature’, American Journal of Surgical Pathology, 29(12), pp. 1558-1575.
  2. Izubuchi, Y. and Tanaka, T. (2025) ‘PEComa-its clinical features, histopathology, and current therapy’, Japanese Journal of Clinical Oncology, 55(7), pp. 691-698.
  3. Wagner, A.J. et al. (2021) ‘nab-Sirolimus for patients with malignant perivascular epithelioid cell tumors’, Journal of Clinical Oncology, 39(33), pp. 3660-3670.
  4. Wagner, A.J. et al. (2024) ‘Phase II trial of nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (AMPECT): long-term efficacy and safety update’, Journal of Clinical Oncology, 42(13), pp. 1472-1476.
  5. Henske, E.P. et al. (2016) ‘Tuberous sclerosis complex’, Nature Reviews Disease Primers, 2, 16035.
  6. Hamza, A. and Guo, C.C. (2020) ‘Perivascular epithelioid cell tumor of the urinary bladder: a systematic review’, International Journal of Surgical Pathology, 28(4), pp. 393-400.
  7. National Cancer Institute (2026) Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/adult-soft-tissue-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.